Analysts Issue Forecasts for NMRA FY2029 Earnings

Neumora Therapeutics, Inc. (NASDAQ:NMRA) – Stock analysts at William Blair issued their FY2029 earnings per share estimates for Neumora Therapeutics in a report issued on Thursday, January 2nd. William Blair analyst M. Minter expects that the company will post earnings of $1.47 per share for the year. The consensus estimate for Neumora Therapeutics’ current full-year earnings is ($1.61) per share.

A number of other equities analysts also recently weighed in on NMRA. Needham & Company LLC reaffirmed a “buy” rating and set a $23.00 price target on shares of Neumora Therapeutics in a research report on Thursday, January 2nd. Bank of America lowered their price target on Neumora Therapeutics from $22.00 to $7.00 and set a “buy” rating on the stock in a research report on Monday. HC Wainwright reissued a “buy” rating and issued a $30.00 price objective on shares of Neumora Therapeutics in a research report on Friday, January 3rd. Royal Bank of Canada cut Neumora Therapeutics from an “outperform” rating to a “sector perform” rating and dropped their price target for the stock from $29.00 to $4.00 in a report on Thursday, January 2nd. Finally, JPMorgan Chase & Co. cut shares of Neumora Therapeutics from an “overweight” rating to a “neutral” rating and dropped their price objective for the stock from $18.00 to $15.00 in a research note on Tuesday, November 5th. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $16.50.

Neumora Therapeutics Stock Up 4.0 %

Shares of NMRA stock opened at $2.58 on Monday. Neumora Therapeutics has a 12-month low of $1.83 and a 12-month high of $21.00. The firm has a fifty day moving average of $10.10 and a 200-day moving average of $11.42. The company has a market capitalization of $416.83 million, a price-to-earnings ratio of -1.38 and a beta of 2.71.

Neumora Therapeutics (NASDAQ:NMRA) last posted its earnings results on Tuesday, November 12th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.06). During the same period last year, the company earned ($1.14) earnings per share.

Insider Transactions at Neumora Therapeutics

In related news, Director Matthew K. Fust sold 14,049 shares of the stock in a transaction that occurred on Friday, October 18th. The shares were sold at an average price of $17.03, for a total value of $239,254.47. Following the completion of the transaction, the director now owns 20,100 shares of the company’s stock, valued at $342,303. This represents a 41.14 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 26.40% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Amalgamated Bank grew its stake in shares of Neumora Therapeutics by 472.8% in the second quarter. Amalgamated Bank now owns 2,910 shares of the company’s stock worth $29,000 after purchasing an additional 2,402 shares during the last quarter. Quarry LP acquired a new stake in Neumora Therapeutics during the 2nd quarter valued at approximately $98,000. SkyOak Wealth LLC bought a new position in Neumora Therapeutics during the 2nd quarter worth approximately $147,000. Principal Financial Group Inc. acquired a new position in shares of Neumora Therapeutics in the 2nd quarter worth approximately $166,000. Finally, Intech Investment Management LLC bought a new stake in shares of Neumora Therapeutics in the 3rd quarter valued at $175,000. 47.65% of the stock is currently owned by institutional investors and hedge funds.

Neumora Therapeutics Company Profile

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.